David L Cooper

List of Publications by Year
in descending order

56	445	759055 12	794469 19
papers	citations	h-index	g-index

56	56	56	660
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1035-1045.	1.0	3
2	Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data . Journal of Blood Medicine, 2019, Volume 10, 243-250.	0.7	0
3	Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC) . Journal of Blood Medicine, 2019, Volume 10, 335-340.	0.7	14
4	Consistency of Dosing of Turoctocog Alfa Pegol (N8-GP) throughout the Pathfinder Clinical Trials: Implications for Recommendations for Effective Prophylaxis, Bleed Resolution, and Perioperative Management. Blood, 2019, 134, 3635-3635.	0.6	2
5	An Update on rFVIIa Use in Females with Rare Bleeding Disorders. Blood, 2019, 134, 1119-1119.	0.6	2
6	Disease Burden in Patients with Glanzmann Thrombasthenia: Perspectives from the Glanzmann Thrombasthenia Patient/Caregiver Questionnaire. Blood, 2019, 134, 3456-3456.	0.6	1
7	Factors associated with pain severity, pain interference, and perception of functional abilities independent of joint status in <scp>US</scp> adults with hemophilia: Multivariable analysis of the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 25-33.	1.1	21
8	Evaluation of bleeding disorders in patients with Noonan syndrome: a systematic review. Journal of Blood Medicine, 2018, Volume 9, 185-192.	0.7	35
9	Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency. Journal of Blood Medicine, 2018, Volume 9, 227-239.	0.7	9
10	Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic. Journal of Blood Medicine, 2018, Volume 9, 211-218.	0.7	14
11	Thrombotic Events with NovoSevenÂ® RT in Approved Indications Are Rare (0.2%) and Associated with Older Age (>= 65 y), Cardiovascular Disease, and Concomitant Use of aPCCs. Blood, 2018, 132, 1203-1203.	0.6	1
12	Impact of mild to severe hemophilia on engagement in recreational activities by US men, women, and children with hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€HEROâ€S) study. European Journal of Haematology, 2017, 98, 25-34.	1.1	16
13	Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. American Journal of Hematology, 2017, 92, 646-652.	2.0	10
14	Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. American Journal of Hematology, 2017, 92, 940-945.	2.0	5
15	Management of <scp>US</scp> men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€<scp>HERO</scp>â€S) study. European Journal of Haematology, 2017, 98, 5-17.	1.1	25
16	Impact of mild to severe hemophilia on education and work by <scp>US</scp> men, women, and caregivers of children with hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€HEROâ€S) study. European Journal of Haematology, 2017, 98, 18-24.	1.1	27
17	Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1603-1612.	0.8	15
18	A global quantitative survey of hemostatic assessment in postpartum hemorrhage and experience with associated bleeding disorders. International Journal of Women's Health, 2017, Volume 9, 477-485.	1.1	3

#	Article	IF	Citations
19	Identification of patients with congenital hemophilia in a large electronic health record database. Journal of Blood Medicine, 2017, Volume 8, 131-139.	0.7	7
20	Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1369-1380.	0.8	20
21	Identification of people with acquired hemophilia in a large electronic health record database. Journal of Blood Medicine, 2017, Volume 8, 89-97.	0.7	7
22	Recognition and management of platelet-refractory bleeding in patients with Glanzmann’s thrombasthenia and other severe platelet function disorders. International Journal of General Medicine, 2017, Volume 10, 95-99.	0.8	14
23	Epistaxis as a Common Presenting Symptom of Glanzmannâ€™s Thrombasthenia, a Rare Qualitative Platelet Disorder: Illustrative Case Examples. Case Reports in Emergency Medicine, 2017, 2017, 1-6.	0.1	6
24	The Relationship of Joint Range of Motion to Factor Activity in Patients with Hemophilia A and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset. Blood, 2017, 130, 756-756.	0.6	1
25	The Coags Uncomplicated App: Fulfilling Educational Gaps Around Diagnosis and Laboratory Testing of Coagulation Disorders. JMIR Medical Education, 2017, 3, e6.	1.2	3
26	Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. Pediatric Blood and Cancer, 2016, 63, 1822-1828.	0.8	8
27	Heavy Menstrual Bleeding as a Common Presenting Symptom of Rare Platelet Disorders: Illustrative Case Examples. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 537-541.	0.3	21
28	Women leaders in hematology: Inspirations & insights. American Journal of Hematology, 2016, 91, S3-5.	2.0	1
29	Challenges in transition to adulthood for young adult patients with hemophilia: Quantifying the psychosocial issues and developing solutions. American Journal of Hematology, 2015, 90, S1-2.	2.0	3
30	Unmet needs in the transition to adulthood: 18- to 30-year-old people with hemophilia. American Journal of Hematology, 2015, 90, S17-S22.	2.0	15
31	Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18â€“30 years) with hemophilia. American Journal of Hematology, 2015, 90, S3-10.	2.0	53
32	Safety and Efficacy of Recombinant Factor VIIa (rFVIIa) in Congenital Hemophilia with Inhibitors (CHwI) in the Home Treatment Setting: Systematic Review of Clinical Studies and Registries. Blood, 2015, 126, 2302-2302.	0.6	5
33	Is Bleeding In Hemophilia Really Spontaneous Or Activity Related: Analysis Of US Patient/Caregiver Data From The Hemophilia Experiences, Results and Opportunities (HERO) Study. Blood, 2013, 122, 2364-2364.	0.6	3
34	Methodological Considerations In The Assessment Of Comorbidities Among Patients With Hemophilia Using Retrospective Claims Data. Blood, 2013, 122, 2947-2947.	0.6	2
35	Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey. Journal of Multidisciplinary Healthcare, 2012, 5, 277.	1.1	19
36	US Experience with Recombinant Factor VIIa (rFVIIa) for Surgery in Acquired Hemophilia (AH): Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry. Blood, 2012, 120, 3372-3372.	0.6	5

#	Article	IF	Citations
37	Use of Recombinant Factor VIIa (rFVIIa) for Acute Bleeding Episodes in Acquired Hemophilia: Final Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Study. Blood, 2012, 120, 4624-4624.	0.6	4
38	The Hemostasis and Thrombosis Research Society (HTRS) Registry Study of Acquired Hemophilia: Assessment of AH Patient Demographics in the US. Blood, 2012, 120, 4625-4625.	0.6	1
39	Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life. Blood, 2012, 120, 4244-4244.	0.6	0
40	A Novel Approach to Capturing Post-Marketing Safety Information On Recombinant Factor VIIa (rFVIIa) in Acquired Hemophilia: Final Data From the Acquired Hemophilia Surveillance (AHS) Project. Blood, 2012, 120, 3371-3371.	0.6	1
41	Recombinant Factor VIIa (rFVIIa) Is Safe and Effective When Used to Treat Acute Bleeding Episodes and to Prevent Bleeding During Surgery in Patients with Acquired Hemophilia: Updated Assessment From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Database,. Blood, 2011, 118, 3374-3374.	0.6	2
42	Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,. Blood, 2011, 118, 3316-3316.	0.6	0
43	Intra-Patient Variability in Recombinant Activated FVII (rFVIIa) Dosing Over 3 to 8 Year Periods in Patients with Congential Hemophilia with Inhibitors Experiencing Frequent Acute Bleeding Episodes: Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry,. Blood, 2011, 118, 3314-3314.	0.6	0
44	Safety of Exposure to Recombinant Activated FVII (rFVIIa) Doses In Patients with Hemophilia and Inhibitors (CHwI) to Factors VIII or IX.. Blood, 2010, 116, 3675-3675.	0.6	1
45	The Acquired Hemophilia Surveillance (AHS) Project: A Novel Mechanism of Capturing Post-Marketing Safety Information on rFVIIa (NovoSevenÂ®RT) In Acquired Hemophilia.. Blood, 2010, 116, 3674-3674.	0.6	0
46	Barriers to the Effective Diagnosis and Management of a Bleeding Patient with Undiagnosed Bleeding Disorder Across Multiple Specialties: Results of a Quantitative Case-Based Survey.. Blood, 2010, 116, 3673-3673.	0.6	1
47	Diary Observational Study in Hemophilia (DOSE): Evaluation of Enrolled Population and Overall Diary Data Capture in Congenital Hemophilia Patients with Alloantibody Inhibitors.. Blood, 2009, 114, 3484-3484.	0.6	1
48	Surgical Experience with Recombinant FVIIa (rFVIIa) in Patients with Hemophilia and Inhibitors to Factors VIII or IX.. Blood, 2009, 114, 1304-1304.	0.6	0
49	Use of Higher Doses of rFVIIa in Individuals with Congenital Hemophilia Complicated by Alloantibody Inhibitors: Analysis of Data Capture from the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004â€“2008). Blood, 2008, 112, 4508-4508.	0.6	1
50	Recombinant Activated Factor VII (rFVIIa) Dosing and Efficacy in the Treatment of Cranial Hemorrhage in Hemophilia Patients with Inhibitors: An Analysis of the Hemophilia and Thrombosis Research Society Registry (HTRS) (2004â€“2008).. Blood, 2008, 112, 2278-2278.	0.6	7
51	Use of rFVIIa in Individuals with Congenital Hemophilia B Complicated by Alloantibody Inhibitors to Factor IX: Analysis of Data Capture from the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004â€“2008). Blood, 2008, 112, 4521-4521.	0.6	0
52	Use of Single Dose of rFVIIa in Congenital Hemophilia: Analysis of Data Capture from the Hemophilia and Thrombosis Research Society Registry (2004â€“2008). Blood, 2008, 112, 4509-4509.	0.6	0
53	Assessing the Impact of Age and Inhibitor Status on Functional Limitations of Patients with Severe and Moderately Severe Hemophilia a: Analysis from the Hemophilia and Thrombosis Research Society (HTRS) Registry.. Blood, 2008, 112, 3395-3395.	0.6	0
54	Bioequivalence, Heat Stability and Reconstitution of Room Temperature Stable Recombinant Activated Factor VII (rFVIIa-RT). Blood, 2008, 112, 4083-4083.	0.6	0

#	Article	IF	Citations
55	The Robustness, Validity, and Potential Usefulness of Registry Data for Understanding the Treatment Practices, Safety, and Efficacy of New Therapies for Rare Bleeding Disorders: The Experience of the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004â€“2007). Blood, 2008, 112, 4506-4506.	0.6	0
56	Critical Pathways for the Management of Stroke and Intracerebral Hemorrhage. Critical Pathways in Cardiology, 2007, 6, 18-23.	0.2	30